Provided are compositions and methods relating to methods and compositions to treat tendon injury.

The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.

The present invention relates to unit dosage forms of 3D-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (Aramchol™) and use thereof in the treatment and/or inhibition of fibrosis.

This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.

The present invention discloses a use of mitochondria to promote wound repair and/or healing. Specifically, when a certain amount of mitochondria or a composition containing a certain amount of mitochondria is administered to a wound, the effect of promoting wound repair or accelerating wound healing can be effectively achieved.

Provided herein are compositions and methods for the treatment of autoimmune and alloimmune diseases and conditions, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis), optic neuritis, Neuromyelitis Optica, Sjögren's syndrome, psoriasis, systemic scleroderma, Ankylosing Spondylitis, autoimmune hepatitis, Graft vs host disease (GvHD), and organ transplant rejection. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.

Provided herein are compositions and methods for the treatment of autoimmune and alloimmune diseases and conditions, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis), optic neuritis, Neuromyelitis Optica, Sjögren's syndrome, psoriasis, systemic scleroderma, Ankylosing Spondylitis, autoimmune hepatitis, Graft vs host disease (GvHD), and organ transplant rejection. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.